VBP15, a Novel Anti-Inflammatory, is Effective at Reducing the Severity of Murine Experimental Autoimmune Encephalomyelitis

Authors

Blythe C. Dillingham
Susan M. Knoblach, George Washington University
Gina M. Many, George Washington University
Brennan Harmon
Amanda Mullen
Christopher R. HeierFollow
Luca Bello
John M. McCall
Eric P. Hoffman, George Washington UniversityFollow
Edward M. Connor, George Washington University
Kanneboyina Nagaraju, George Washington University
Erica M.K. Reeves
Jesse M. DamskerFollow

Document Type

Journal Article

Publication Date

2015

Journal

Cellular and Molecular Neurobiology

Volume

Volume 35, Issue 3

Inclusive Pages

377-387

DOI

10.1007/s10571-014-0133-y

Keywords

Anti-Inflammatory Agents--therapeutic use; Encephalomyelitis, Autoimmune, Experimental--drug therapy; Pregnadienediols--therapeutic use; Severity of Illness Index

APA Citation

Dillingham, B. C., Knoblach, S. M., Many, G. M., Harmon, B. T., Mullen, A. M., et al. (2015). VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. Cellular and Molecular Neurobiology, 35(3), 377-387.

Peer Reviewed

1